Candriam S.C.A. Ideaya Biosciences, Inc. Transaction History

Candriam S.C.A.

$16.9 Billion
Q4 2024

A detailed history of Candriam S.C.A. transactions in Ideaya Biosciences, Inc. stock. As of the latest transaction made, Candriam S.C.A. holds 1,071,825 shares of IDYA stock, worth $23.5 Million. This represents 0.16% of its overall portfolio holdings.

Number of Shares

1,071,825

Previous 940,440 13.97%

Holding current value

$23.5 Million

Previous $29.8 Million 7.55%

% of portfolio

0.16%

Previous 0.17%

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 06, 2025	BUY	$24.79 - $31.98 $3.26 Million - $4.2 Million	131,385 Added 13.97%	1,071,825 $27.5 Million
Q3 2024 Nov 13, 2024	BUY	$30.37 - $43.05 $9.46 Million - $13.4 Million	311,421 Added 49.51%	940,440 $29.8 Million
Q2 2024 Aug 05, 2024	SELL	$34.37 - $43.46 $34,370 - $43,460	-1,000 Reduced 0.16%	629,019 $22.1 Million
Q1 2024 May 03, 2024	BUY	$34.2 - $47.13 $8.04 Million - $11.1 Million	235,000 Added 59.49%	630,019 $27.6 Million
Q4 2023 Feb 14, 2024	SELL	$24.59 - $35.83 $860,650 - $1.25 Million	-35,000 Reduced 8.14%	395,019 $14.1 Million
Q3 2023 Nov 13, 2023	BUY	$21.07 - $29.77 $421,378 - $595,370	19,999 Added 4.88%	430,019 $11.6 Million
Q2 2023 Aug 08, 2023	BUY	$13.33 - $25.53 $1.73 Million - $3.31 Million	129,703 Added 46.27%	410,020 $9.64 Million
Q4 2022 Feb 13, 2023	BUY	$14.47 - $18.17 $361,750 - $454,250	25,000 Added 9.79%	280,317 $5.09 Million
Q3 2022 Nov 10, 2022	BUY	$9.24 - $15.79 $2.36 Million - $4.03 Million	255,317 New	255,317 $3.81 Million

Others Institutions Holding IDYA

# of Institutions

224

Shares Held

83M

Call Options Held

69K

Put Options Held

20K

View Full List

About IDEAYA Biosciences, Inc.

Ticker IDYA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,067,700
Market Cap $1.06B
Description
IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's lead product candidates include IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase I clinica...

More about IDYA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Candriam S.C.A., based on Form 13F filings with the SEC.

News

Stay updated on Candriam S.C.A. with notifications on news.

Account